Publications

2026

Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.
Goldberg SB, Ahn MJ, Baik C, De Castro Carpeño J, Cho BC, de Langen AJ, Fidler MJ, Goldman JW, Grønberg BH, Akamatsu H, Kim SW, Kim YJ, Le X, Marrone KA, Piotrowska Z, Riess JW, Shiraishi Y, Fraenkel PG, Merchan Ruiz B, Smith PE, Tang KH, Yu HA. Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD. Clin Cancer Res 2026 PMID: 42440354, DOI: 10.1158/1078-0432.CCR-26-0704.
Peer-Reviewed Original Research
This study investigates combining osimertinib and gefitinib in advanced lung cancer with EGFR C797S mutation, showing modest benefits but highlighting tumor resistance and limited efficacy.
Full Summary
Tumor characteristics associated with tomosynthesis versus digital mammography in older women with screen-detected breast cancer
Huang S, Westvold SJ, Soulos PR, Lewin JM, Zhan H, Lustberg MB, Greenup RA, Richman IB, Winer EP, Robinson TJ, Dinan MA. Tumor characteristics associated with tomosynthesis versus digital mammography in older women with screen-detected breast cancer. Breast Cancer Research And Treatment 2026, 218: 4. DOI: 10.1007/s10549-026-08013-4.
Peer-Reviewed Original Research
This study investigates the benefits of digital breast tomosynthesis over conventional mammography in older women, showing limited advantage in detecting smaller tumors or invasive lobular carcinoma at age ≥75.
Full Summary
Medical Management of Non-Small Cell Lung Cancer Brain Metastases in the Modern Era.
Lu BY, Goldberg SB. Medical Management of Non-Small Cell Lung Cancer Brain Metastases in the Modern Era. Cancer J 2026, 32 PMID: 42497398, DOI: 10.1097/PPO.0000000000000840.
Peer-Reviewed Original Research
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax—an analysis from the International Consortium for MDS (icMDS) VALIDATE database
Bewersdorf JP, Kewan T, Lanino L, Wei W, Rudra Gupta T, Stempel JM, Al Ali NH, DeZern AE, Sekeres MA, Uy GL, Urrutia S, Carraway HE, Desai P, Griffiths EA, Stein EM, Brunner AM, McMahon C, Shallis RM, Zeidner JF, Savona MR, Hawkins H, Chandhok NS, Logothetis CN, Bidikian A, Getz TM, Roboz GJ, Rolles B, Wang ES, Harris AC, Amaya ML, Ball S, Grenet J, Xie Z, Madanat YF, Abaza Y, Badar T, Campos J, Haferlach T, Maciejewski JP, Sallman D, Enjeti A, Al-Rabi K, Halahleh K, Hiwase D, Diez-Campelo M, Valcarcel D, Haferlach C, Pleyer L, Kotsianidis I, Pappa V, Santini V, Consagra A, Al-Kali A, Ogawa S, Nannya Y, Stahl M, Della Porta MG, Komrokji RS, Zeidan AM. Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax—an analysis from the International Consortium for MDS (icMDS) VALIDATE database. Blood Cancer Journal 2026 DOI: 10.1038/s41408-026-01543-6.
Peer-Reviewed Original Research
This study investigates the impact of combining hypomethylating agents with venetoclax for high-risk myelodysplastic syndromes, finding increased remission rates but no significant overall survival benefit.
Full Summary
The transcription factor Eomes drives a stemness program in CD4(+) T cells that promotes anti-tumor immunity in response to immunotherapy.
Agesta A, Ferrand C, Le Dorze AL, Peillex C, Carrié N, Barascud R, Palak A, Esteban L, Bernal T, Joulia E, Colacios C, Pereira TM, Peroceschi R, Pichler A, Chaubet A, Zahm M, Saoudi A, El Costa H, Adoue V, Lu BY, Lucca LE, Martinet L, Dejean AS. The transcription factor Eomes drives a stemness program in CD4(+) T cells that promotes anti-tumor immunity in response to immunotherapy. Immunity 2026 PMID: 42341755, DOI: 10.1016/j.immuni.2026.05.018.
Peer-Reviewed Original Research
Half a century of pneumococcal vaccination in sickle cell disease: Are we winning the battle or losing immunity?
Jamwal S, Omene B, Giri A, Rojas K, Mohanty S, Calhoun C, Krishnamurti L, Montgomery R, Shaw A, Andemariam B, Yildirim I. Half a century of pneumococcal vaccination in sickle cell disease: Are we winning the battle or losing immunity? Vaccine 2026, 88: 128866. PMID: 42322679, DOI: 10.1016/j.vaccine.2026.128866.
Peer-Reviewed Original Research
Concepts
Management Algorithm for Vasoplegic Shock after Cardiac Surgery: An Interdisciplinary Collaboration
Chatterjee S, Ortoleva J, Arora R, Dalton K, Engelman D, Girardi N, Grant M, Miles T, Moon M, Suero O, Wittwer E, Wieruszewski P. Management Algorithm for Vasoplegic Shock after Cardiac Surgery: An Interdisciplinary Collaboration. The Annals Of Thoracic Surgery 2026 PMID: 42309294, DOI: 10.1016/j.athoracsur.2026.06.013.
Peer-Reviewed Original Research
Concepts
Cumulative Antigen Suppression Reduces Clonal Plasma Cell Evolution in Gaucher Disease
Ain N, Bar N, Guo L, Klinger K, Gupta P, Rahman A, Yang R, Deng Y, Neparidze N, Nair S, Mistry P. Cumulative Antigen Suppression Reduces Clonal Plasma Cell Evolution in Gaucher Disease. American Journal Of Hematology 2026 PMID: 42309787, DOI: 10.1002/ajh.70407.
Peer-Reviewed Original Research
Concepts
Beyond the Catalogue: Design and Biological Enrichment as the Next Priorities in Higher‐Risk MDS Drug Development
Zeidan A, Bono P, Williamson J. Beyond the Catalogue: Design and Biological Enrichment as the Next Priorities in Higher‐Risk MDS Drug Development. European Journal Of Haematology 2026 PMID: 42304846, DOI: 10.1111/ejh.70244.
Peer-Reviewed Original Research
Concepts
Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapy
Notini G, Galbardi B, Viale G, Naldini M, Bosi C, De Micheli G, Licata L, Mariani M, Piras M, Criscitiello C, Barreca M, Callari M, Zanibelli C, Patanè F, Chiavassa A, Pérez-García J, Ali H, Córtes J, Pusztai L, Gianni L, Bianchini G, Dugo M. Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapy. Npj Precision Oncology 2026, 10: 218. PMID: 42297906, PMCID: PMC13269767, DOI: 10.1038/s41698-026-01523-w.
Peer-Reviewed Original Research
Concepts
Linker-dependent variations in the tumoricidal activity of DZ-1–dihydroartemisinin conjugate formats
Vafaeinik F, Helmueller S, Zhang Y, Gangi A, Lee H, Song C, Figlin R, Sargsyan K, Lee Y. Linker-dependent variations in the tumoricidal activity of DZ-1–dihydroartemisinin conjugate formats. Biomedicine & Pharmacotherapy 2026, 201: 119654. PMID: 42296912, DOI: 10.1016/j.biopha.2026.119654.
Peer-Reviewed Original Research
Concepts
The International Academy for Clinical Hematology (IACH) 2026–2030 strategic vision and roadmap: Building the global reference for education, collaboration, and innovation in clinical hematology
Mohty M, Savani B, Bazarbachi A, Blaise D, Huang H, Malard F, Kharfan-Dabaja M, Facon T, Brissot E, Peric Z, Ruggeri A, Zeidan A, Pemmaraju N, Shoham Z, Melo J, Nagler A. The International Academy for Clinical Hematology (IACH) 2026–2030 strategic vision and roadmap: Building the global reference for education, collaboration, and innovation in clinical hematology. Clinical Hematology International 2026, 8: 59-62. PMCID: PMC13273739, DOI: 10.46989/001c.163209.
Peer-Reviewed Original Research
Concepts
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus
Aragon-Ching J, Gupta S, Grivas P, Park S, Petrylak D, Sridhar S, Gurney H, Jacob N, Tyroller K, Hoffman J, Bellmunt J. Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus. ESMO Open 2026, 11: 107776. PMID: 42284622, PMCID: PMC13279007, DOI: 10.1016/j.esmoop.2026.107776.
Peer-Reviewed Original Research
Concepts
Real-World Utilization of Daratumumab in Front-Line Treatment of Newly Diagnosed Multiple Myeloma Across a Regional Academic–Community Network
Theprungsirikul P, Al-Musa A, Bar N, Browning S, Parker T, Neparidze N. Real-World Utilization of Daratumumab in Front-Line Treatment of Newly Diagnosed Multiple Myeloma Across a Regional Academic–Community Network. Cancers 2026, 18: 1899. PMID: 42352434, PMCID: PMC13297397, DOI: 10.3390/cancers18121899.
Peer-Reviewed Original Research
Concepts
Real-World Overall Survival and Time to Next Treatment Among Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Frontline Setting
Huntington S, Puckett J, Manzoor B, Emechebe N, Li S, Kamal-Bahl S, Reyes C, Budlong H, Doshi J. Real-World Overall Survival and Time to Next Treatment Among Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Frontline Setting. Cancers 2026, 18: 1902. PMID: 42352437, PMCID: PMC13297127, DOI: 10.3390/cancers18121902.
Peer-Reviewed Original Research
Concepts
Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer.
Main S, Elliott M, Singhawansa A, Zou J, Zeng Y, Cheng N, Yu C, Hilton J, Awadalla P, He H, Bedard P, Lupien M, Bratman S, Cescon D. Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer. Cancer Research 2026 PMID: 42268298, DOI: 10.1158/0008-5472.can-26-0076.
Peer-Reviewed Original Research
Concepts
Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.
Schöffski P, Sanfilippo R, Martín-Broto J, Kawai A, Desai J, LoRusso P, Maki R, Jones R, Blay J, Smrke A, Abdul Razak A, Italiano A, Sebio A, Bahleda R, Lee Y, van der Graaf W, Zhang X, Biyukov T, Teufel M, Fu E, Lahmar M, Wagner A. Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial. Clinical Cancer Research 2026 PMID: 42268294, DOI: 10.1158/1078-0432.ccr-26-0509.
Peer-Reviewed Original Research
Concepts
Dihydropyrimidine dehydrogenase testing: From Pharmacogenomics to Equitable Practice.
Gaddy J, Kunz P, Sundar R. Dihydropyrimidine dehydrogenase testing: From Pharmacogenomics to Equitable Practice. Clinical Cancer Research 2026, of1-of3. PMID: 42262381, DOI: 10.1158/1078-0432.ccr-26-0952.
Peer-Reviewed Original Research
Concepts
Advances in Cancer Immunotherapy for Solid Tumors
Gabizon‐Peretz S, Kluger H. Advances in Cancer Immunotherapy for Solid Tumors. Advanced Science 2026, 13: e76020. PMID: 42261754, PMCID: PMC13292180, DOI: 10.1002/advs.76020.
Peer-Reviewed Original Research
MeSH Keywords and Concepts
Factors in Implementation of ASH SCD Guidelines on Cognition and Silent Cerebral Infarcts at a Single Sickle Cell Center.
Afranie-Sakyi J, Karimi M, Restrepo V, Bozzo J, Cole J, Van Doren L, Calhoun C. Factors in Implementation of ASH SCD Guidelines on Cognition and Silent Cerebral Infarcts at a Single Sickle Cell Center. Blood Advances 2026 PMID: 42263745, DOI: 10.1182/bloodadvances.2025018268.
Peer-Reviewed Original Research
Exploring current cancer screening practices and guidelines for adults under age 50 in the United States
Reedy J, Borstelmann N, Giri V. Exploring current cancer screening practices and guidelines for adults under age 50 in the United States. Frontiers In Public Health 2026, 14: 1816070. PMID: 42338536, PMCID: PMC13284104, DOI: 10.3389/fpubh.2026.1816070.
Peer-Reviewed Original Research
MeSH Keywords and Concepts
Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis
Alhajahjeh A, Beke K, Grimshaw A, Aguirre L, Mina A, Podoltsev N, Mendez L, Stahl M, Zeidan A, Bewersdorf J. Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis. Leukemia & Lymphoma 2026, 67: 1662-1674. PMID: 42251692, DOI: 10.1080/10428194.2026.2682397.
Peer-Reviewed Original Research
Concepts
All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia
Roboz GJ, Zeidan AM, Mannis GN, Montesinos P, Arnan M, Savona MR, Odenike O, McCloskey JK, Amin HV, Fathi AT, Bernal del Castillo T, Rodríguez-Macías G, Liesveld JL, Im AP, Cerny J, Gentile TC, Oganesian A, Chan D, Wan Y, Dijkstra M, Keer HN, Griffiths EA, DiNardo CD. All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia. New England Journal Of Medicine 2026, 394 DOI: 10.1056/NEJMoa2510223.
Peer-Reviewed Original Research
This study investigates the safety and efficacy of an all-oral decitabine-cedazuridine plus venetoclax regimen for newly diagnosed acute myeloid leukemia, showing a 47% complete response rate and improved survival with manageable side effects.
Full Summary
Pathogenesis of diffuse large B cell lymphoma proteogenotypes
Enssle J, Häupl B, Qoku A, Wang B, Wright G, Barrans S, Zhou Y, Care M, Burton C, Gribbin C, Ziello J, Weirather J, Dai Y, Kizhakeyil A, Li X, Phelan J, Kanangat S, Eckert S, Scheich S, Wolf S, Huang D, Jakob J, Perner S, Di Fonzo A, Pape M, Bodach M, Jahn D, Plessmann U, Staiger A, Ott G, Berning P, Lenz G, Hodson D, Kuster B, Schmitz R, Urlaub H, Green M, Melnick A, Tooze R, Mlynarczyk C, Inghirami G, Buettner F, Staudt L, Oellerich T. Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer Cell 2026 PMID: 42242231, DOI: 10.1016/j.ccell.2026.05.008.
Peer-Reviewed Original Research
Concepts
Methylation-based ctDNA monitoring in metastatic breast cancer during CDK4/6 inhibitor therapy
Elliott M, Fuentes-Antrás J, Main S, Dou A, Shah E, Weipert C, Yalamanchili G, Bird T, Roh J, Yu C, Nadler M, Amir E, Berman H, Siu L, Bedard P, Cescon D. Methylation-based ctDNA monitoring in metastatic breast cancer during CDK4/6 inhibitor therapy. Nature Communications 2026 PMID: 42243127, DOI: 10.1038/s41467-026-73126-9.
Peer-Reviewed Original Research
Concepts

See All Publications